Cite
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
MLA
Berger, Jeffrey S., et al. “Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-Valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.” Advances in Therapy, vol. 40, no. 3, Mar. 2023, pp. 1224–41. EBSCOhost, https://doi.org/10.1007/s12325-022-02422-9.
APA
Berger, J. S., Ashton, V., Laliberté, F., Germain, G., Bookhart, B., Lejeune, D., Boudreau, J., Lefebvre, P., & Weir, M. R. (2023). Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population. Advances in Therapy, 40(3), 1224–1241. https://doi.org/10.1007/s12325-022-02422-9
Chicago
Berger, Jeffrey S, Veronica Ashton, François Laliberté, Guillaume Germain, Brahim Bookhart, Dominique Lejeune, Julien Boudreau, Patrick Lefebvre, and Matthew R Weir. 2023. “Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-Valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.” Advances in Therapy 40 (3): 1224–41. doi:10.1007/s12325-022-02422-9.